* Genzyme Corp., of Cambridge, Mass., has entered its secondresearch collaboration in a month to develop a gene therapy fortreatment of Gaucher's disease. The most recent is with University ofPittsburgh Professor John Barranger. In early October, the companysigned an agreement with Netherlands-based IntroGene B.V.Genzyme already markets two drugs, Ceredase and Cerezyme, fortreatment of Gaucher's disease.* InSite Vision Inc., of Alameda, Calif., has completed enrollment ofmore than 645 patients with ocular hypertension or open-angleglaucoma for a Phase III clinical trial of the company's BetaSiteeyedrops. The study began in January and patient treatments couldbe completed by the end of this year.* Cytel Corp., of San Diego, said Friday that SumitomoPharmaceuticals Co. Ltd., of Osaka, Japan, completed a $5 millionequity investment in Cytel. Sumitomo and Cytel have beencollaborating since 1991 on the development of drugs based onCytel's cell-adhesion technology. Sumitomo bought about 1.4million shares at $3.55 apiece, bringing Cytel's outstanding shares to18.4 million.* Glyko Biomedical Ltd., of Novato, Calif., and Bio-RadLaboratories, of Hercules, Calif., signed a letter of intent in whichGlyko will provide its line of FACE analytical imagers and reagentsto be marketed under the Bio-Rad label. The nonexclusive agreementstill is subject to negotiation.* InSite Vision Inc., of Alameda, Calif., obtained an exclusiveworldwide license from the University of California (UC) to thecDNA sequence that codes for a peptide associated with glaucoma.The company and UC-San Francisco plan to use the sequence todevelop genetic screening tools for glaucoma.* Myriad Genetics Inc., Salt Lake City, said it moved to new 25,000-square-foot research and administrative headquarters in theUniversity of Utah Research Park.* Spectral Diagnostics Inc., Toronto, said it acquired an exclusivehuman cardiac gene bank as part of a three-year research agreementwith the University of Toronto.* Telor Ophthalmic Pharmaceuticals Inc., of Wilmington, Mass.,said its Phase II trial of Tekron, a topical eye-drop formulation ofethacrynic acid, failed to show efficacy vs. placebo in reducingintraocular pressure. The company will not proceed with clinicaldevelopment of topical ethacrynic acid for that indication.* Texas Biotechnology Corp., of Houston, said its shareholdersapproved the acquisition of San Diego-based ImmunoPharmaceuticsInc., a rational drug design company.* Isis Pharmaceuticals Inc., of Carlsbad, Calif., is beginning a PhaseI trial in the U.K. for ISIS 2302, an antisense oligonucleotide thatinhibits the expression of intercellular adhesion molecule-1, which isimplicated in organ transplant rejection and various inflammatorydiseases.* AMDL Inc., of Pasadena, Calif., said enrollment of 250 lungcancer patients is expected to be completed in 30 days for the trial ofits DR-70 tumor-marker detection kit.* Empresas La Moderna, of Mexico, an affiliate of the PulsarInternacional group of companies, signed a purchase agreement toacquire the Asgrow Seed Co. subsidiary of the Upjohn Co., ofKalamazoo, Mich. The purchase price is estimated at $300 million.The deal is expected to close Dec. 30.* Gensia Inc., of San Diego, said it completed the initial stage of itspreviously announced collaboration with Boehringer MannheimPharmaceuticals Corp., of Gaithersburg, Md., and London-basedCorange International Ltd. after receiving antitrust clearance. Gensiareceived a $10 million up-front and $10 million in equity in a dealthat could be worth $64.5 million (See BioWorld Today, Oct. 12,1994, p.1.).
(c) 1997 American Health Consultants. All rights reserved.